Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biologicals ; 51: 54-61, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29107446

RESUMO

We describe the characterisation of a novel monoPEGylated recombinant human granulocyte colony-stimulating factor analogue, pegteograstim (Neulapeg), prepared by site-specific 20 kDa maleimide-PEG conjugation. An additional cysteine was inserted between Gly136 and Ala137 of filgrastim (methionyl human granulocyte colony-stimulating factor) for site-specific PEGylation, and Cys18 of filgrastim was replaced with Ser18 to prevent unwanted PEGylation. Pegteograstim was produced by Escherichia coli and purified by cation exchange chromatography, and its structural, physicochemical, biological and immunological properties were investigated. Male Sprague-Dawley rats were administered pegteograstim (100 µg/kg) and the pharmacokinetics and pharmacodynamics compared with those of filgrastim. The results of long-term stability testing of pegteograstim revealed no significant change in its quality attributes at 2-8 °C for 36 months. In addition, pegteograstim was stable under the accelerated conditions (25 ± 2 °C, RH of 60 ± 5%) for 6 months. The site-specific monoPEGylated pegteograstim is a highly pure, stable and novel drug for long-lasting treatment of chemotherapy-induced neutropenia.


Assuntos
Filgrastim/química , Fator Estimulador de Colônias de Granulócitos/química , Polietilenoglicóis/química , Proteínas Recombinantes/química , Sequência de Aminoácidos , Animais , Sítios de Ligação , Linhagem Celular Tumoral , Cisteína/química , Estabilidade de Medicamentos , Filgrastim/administração & dosagem , Filgrastim/farmacocinética , Fator Estimulador de Colônias de Granulócitos/genética , Humanos , Masculino , Camundongos , Neutropenia/prevenção & controle , Ratos Sprague-Dawley
2.
J Hum Genet ; 62(2): 167-174, 2017 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-27829684

RESUMO

Hunter syndrome is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to the accumulation of glycosaminoglycans (GAGs). Two recombinant enzymes, idursulfase and idursulfase beta are currently available for enzyme replacement therapy for Hunter syndrome. These two enzymes exhibited some differences in various clinical parameters in a recent clinical trial. Regarding the similarities and differences of these enzymes, previous research has characterized their biochemical and physicochemical properties. We compared the in vitro and in vivo efficacy of the two enzymes on patient fibroblasts and mouse model. Two enzymes were taken up into the cell and degraded GAGs accumulated in fibroblasts. In vivo studies of two enzymes revealed similar organ distribution and decreased urinary GAGs excretion. Especially, idursulfase beta exhibited enhanced in vitro efficacy for the lower concentration of treatment, in vivo efficacy in the degradation of tissue GAGs and improvement of bones, and revealed lower anti-drug antibody formation. A biochemical analysis showed that both enzymes show largely a similar glycosylation pattern, but the several peaks were different and quantity of aggregates of idursulfase beta was lower.


Assuntos
Terapia de Reposição de Enzimas/métodos , Iduronato Sulfatase/farmacologia , Iduronato Sulfatase/farmacocinética , Iduronato Sulfatase/uso terapêutico , Mucopolissacaridose II/tratamento farmacológico , Animais , Linhagem Celular , Glicoproteínas/genética , Glicosaminoglicanos/metabolismo , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Mucopolissacaridose II/genética , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz
3.
Polymers (Basel) ; 13(1)2020 Dec 29.
Artigo em Inglês | MEDLINE | ID: mdl-33383793

RESUMO

Bovine submaxillary mucin (BSM) is a natural polymer used in biomaterial applications for its viscoelasticity, lubricity, biocompatibility, and biodegradability. N-glycans are important for mucin stability and function, but their structures have not been fully characterized, unlike that of O-glycans. In this study, BSM N-glycans were investigated using liquid chromatography-tandem mass spectrometry. The microheterogeneous structures of 32 N-glycans were identified, and the quantities (%) of each N-glycan relative to total N-glycans (100%) were obtained. The terminal N-acetylgalactosamines in 12 N-glycans (sum of relative quantities; 27.9%) were modified with mono- (10 glycans) and disulfations (2 glycans). Total concentration of all sulfated N-glycans was 6.1 pmol in BSM (20 µg), corresponding to 25.3% of all negatively charged glycans (sum of present N-glycans and reported O-glycans). No N-glycans with sialylated or phosphorylated forms were identified, and sulfate modification ions were the only negative charges in BSM N-glycans. Mucin structures, including sulfated N-glycans located in the hydrophobic terminal regions, were indicated. This is the first study to identify the structures and quantities of 12 sulfated N-glycans in natural mucins. These sulfations play important structural roles in hydration, viscoelasticity control, protection from bacterial sialidases, and polymer stabilization to support the functionality of BSM via electrostatic interactions.

4.
Adv Mater ; 27(43): 6914-21, 2015 Nov 18.
Artigo em Inglês | MEDLINE | ID: mdl-26421382

RESUMO

Pyroprotein-based carbon nanoplates are fabricated from self-assembled silk proteins as a versatile platform to examine sodium-ion storage characteristics in various carbon environments. It is found that, depending on the local carbon structure, sodium ions are stored via chemi-/physisorption, insertion, or nanoclustering of metallic sodium.


Assuntos
Carbono/química , Fontes de Energia Elétrica , Fibroínas/química , Nanoestruturas/química , Sódio/química , Eletroquímica , Modelos Moleculares , Conformação Molecular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA